IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

In re:	Chapter 11
NANOSTRING TECHNOLOGIES, INC., *et al.*,[1]	Case No. 24-10160 (CTG)
	(Jointly Administered)
Debtors.	**Ref. Docket No. 127**

WITHDRAWAL OF MOTION OF 10X GENOMICS, INC. FOR ENTRY OF AN ORDER (I) MODIFYING THE AUTOMATIC STAY WITH RESPECT TO THE 653 ACTION AND THE IPR PROCEEDINGS AND (II) GRANTING RELATED RELIEF

PLEASE TAKE NOTICE that, on February 22, 2024, 10x Genomics, Inc. ("**10x**") filed the *Motion of 10x Genomics, Inc. for Entry of an Order (I) Modifying the Automatic Stay with Respect to the 653 Action and the IPR Proceedings and (II) Granting Related Relief* (D.I. 127) (the "**Stay Relief Motion**")[2] seeking relief from the automatic stay with respect to: (A) *10x Genomics, Inc. and Prognosys Biosciences, Inc. v. NanoString Technologies, Inc.*, Case No. 21-cv-653 (MFK) (D. Del. 2021) (the "**653 Action**"); and (B) two administrative actions pending in the United States Patent and Trademark Office before the Patent Trial and Appeal Board: (I) Case IPR2023-01298 (the "**689 IPR Proceeding**") and (II) Case IPR2023-01300 (the "**142 IPR Proceeding**" and together with the 689 IPR Proceeding and the 653 Action, the "**Litigation Matters**").

[1] The Debtors in these Chapter 11 Cases, along with the last four digits of their U.S. federal tax identification numbers, to the extent applicable, are NanoString Technologies, Inc. (4687), NanoString Technologies International, Inc. (2723), NanoString Technologies Netherlands B.V., and NanoString Technologies Germany GmbH. The Debtors' headquarters is located at 530 Fairview Avenue North, Suite 2000, Seattle, WA 98109.

[2] Capitalized terms not defined herein are defined in the Stay Relief Motion.

PLEASE TAKE FURTHER NOTICE that on April 19, 2024, the Court entered an order (D.I. 470) (the "**Sale Order**") approving the sale of the Debtors' assets to Bruker Corporation. The Sale Order renders the Buyer (as defined in the Sale Order) fully liable for any and all Assumed Liabilities and requires the Buyer to take such actions as reasonably necessary to ensure that all Assumed Litigation Liabilities[3] are promptly transferred to the Buyer on the Closing Date (as defined in the Sale Order) or as promptly as reasonably practicable thereafter and to replace Debtors with the Buyer as the appropriate party in any pending proceedings with respect to the Assumed Litigation Liabilities in compliance with the requirements of the applicable jurisdiction. *See* Sale Order ¶ 9.

PLEASE TAKE FURTHER NOTICE that on May 6, 2024, the sale closed and the Buyer assumed the Assumed Litigation Liabilities.

PLEASE TAKE FURTHER NOTICE that based on the transfer of the Litigation Matters to the Buyer, 10x hereby withdraws its Stay Relief Motion without prejudice.

[*Remainder of Page Intentionally Left Blank*]

[3] Assumed Litigation Liabilities include the Litigation Matters.

Dated: May 9, 2024

Respectfully submitted,

/s/ Sophie Rogers Churchill

Derek C. Abbott (No. 3376)
Sophie Rogers Churchill (No. 6905)
MORRIS, NICHOLS, ARSHT & TUNNELL LLP
1201 North Market Street, 16th Floor
Wilmington, Delaware 19801
Telephone: (302) 658-9200
Facsimile: (302) 658-3989
Email: dabbott@morrisnichols.com
srchurchill@morrisnichols.com

-and-

Kimberly A. Posin (admitted *pro hac vice*)
Amy C. Quartarolo (admitted *pro hac vice*)
LATHAM & WATKINS LLP
355 South Grand Avenue, Suite 100
Los Angeles, CA 90071
Telephone: (213) 485-1234
Facsimile: (213) 891-8763
Email: kim.posin@lw.com
amy.quartarolo@lw.com

-and-

Brian S. Rosen (admitted *pro hac vice*)
Meghana Vunnamadala (admitted *pro hac vice*)
LATHAM & WATKINS LLP
1271 Avenue of the Americas
New York, NY 10020
Telephone: (212) 906-1200
Facsimile: (212) 751-4864
Email: brian.rosen@lw.com
meghana.vunnamadala@lw.com

Counsel to 10x Genomics, Inc.